Bacteriophage-derived vectors for targeted cancer gene therapy

Viruses

Volumn 7, Issue 1, 2015, Pages 268-284

  Pranjol, Md Zahidul Islam ^a   Hajitou, Amin ^b  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

AAVP; Bacteriophage; CMV; Glioblastoma; Grp78; HSVtk; RGD4C AAVP CMV HSVtk; RGD4C AAVP Grp78 HSVtk

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN PROMOTER; ANTINEOPLASTIC AGENT; CARCINO EMBRYONIC ANTIGEN PROMOTER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE REGULATED PROTEIN 78 PROMOTER; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROMOTER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ARTICLE; BACTERIOPHAGE; CANCER GENE THERAPY; CLINICAL TRIAL (TOPIC); GENE EXPRESSION; GENE SILENCING; GENETIC REGULATION; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; LENTIVIRINAE; MEASLES VIRUS; MOLECULARLY TARGETED THERAPY; NONHUMAN; RETROVIRUS; TRANSCRIPTIONAL TARGETING; TUMOR MICROENVIRONMENT; BIOLOGICAL THERAPY; GENE TARGETING; GENE THERAPY; GENETICS; MEDICAL RESEARCH; PROCEDURES; TRENDS; TUMOR GENE;

BACTERIOPHAGES; BIOLOGICAL THERAPY; BIOMEDICAL RESEARCH; GENE TARGETING; GENES, NEOPLASM; GENETIC THERAPY; HUMANS;

EID: 84921726056     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7010268     Document Type: Article

References (63)

1. Gillet, J.P.; Macadangdang, B.; Fathke, R.L.; Gottesman, M.M.; Kimchi-Sarfaty, C. The development of gene therapy: From monogenic recessive disorders to complex diseases such as cancer. Methods Mol. Biol. 2009, 542, 5–54.
2. Friedmann, T. A brief history of gene therapy. Nat. Genet. 1992, 2, 93–98.
3. Rosenberg, S.A.; Aebersold, P.; Cornetta, K.; Kasid, A.; Morgan, R.A.; Moen, R.; Karson, E.M.; Lotze, M.T.; Yang, J.C.; Topalian, S.L.; et al. Gene transfer into humans—Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 1990, 323, 570–578.
4. Edelstein, M.L.; Abedi, M.R.; Wixon, J. Gene therapy clinical trials worldwide to 2007—An update. J. Gene Med. 2007, 9, 833–842.
5. Hajitou, A. Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted aavp vector. Adv. Genet. 2010, 69, 65–82.
6. Sadeghi, H.; Hitt, M.M. Transcriptionally targeted adenovirus vectors. Curr. Gene Ther. 2005, 5, 411–427.
7. Cheng, L.; Ziegelhoffer, P.R.; Yang, N.S. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc. Natl. Acad. Sci. USA 1993, 90, 4455–4459.
8. Rodriguez, R.; Schuur, E.R.; Lim, H.Y.; Henderson, G.A.; Simons, J.W.; Henderson, D.R. Prostate attenuated replication competent adenovirus (arca) cn706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997, 57, 2559–2563.
9. Miyatake, S.; Iyer, A.; Martuza, R.L.; Rabkin, S.D. Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol. 1997, 71, 5124–5132.
10. Robson, T.; Hirst, D.G. Transcriptional targeting in cancer gene therapy. J. Biomed. Biotechnol. 2003, 2003, 110–137.
11. Bao, R.; Selvakumaran, M.; Hamilton, T.C. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter. Gynecol. Oncol. 2002, 84, 228–234.
12. Su, H.; Lu, R.; Chang, J.C.; Kan, Y.W. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice. Proc. Natl. Acad. Sci. USA 1997, 94, 13891–13896.
13. Zhang, R.; Straus, F.H.; DeGroot, L.J. Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid 2001, 11, 115–123.
14. Fecker, L.F.; Ruckert, S.; Kurbanov, B.M.; Schmude, M.; Stockfleth, E.; Fechner, H.; Eberle, J. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand. Hum. Gene Ther. 2011, 22, 405–417.
15. Xiong, J.; Sun, W.J.; Wang, W.F.; Liao, Z.K.; Zhou, F.X.; Kong, H.Y.; Xu, Y.; Xie, C.H.; Zhou, Y.F. Novel, chimeric, cancer-specific, and radiation-inducible gene promoters for suicide gene therapy of cancer. Cancer 2012, 118, 536–548.
16. Bauerschmitz, G.J.; Nettelbeck, D.M.; Kanerva, A.; Baker, A.H.; Hemminki, A.; Reynolds, P.N.; Curiel, D.T. The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Res. 2002, 62, 1271–1274.
17. Glinka, E.M. Eukaryotic expression vectors bearing genes encoding cytotoxic proteins for cancer gene therapy. Plasmid 2012, 68, 69–85.
18. Mizuguchi, H.; Koizumi, N.; Hosono, T.; Utoguchi, N.; Watanabe, Y.; Kay, M.A.; Hayakawa, T. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the hi loop of their fiber knob. Gene Ther. 2001, 8, 730–735.
19. Kim, J.; Kim, P.H.; Kim, S.W.; Yun, C.O. Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials 2012, 33, 1838–1850.
20. Yun, H.J.; Cho, Y.H.; Moon, Y.; Park, Y.W.; Yoon, H.K.; Kim, Y.J.; Cho, S.H.; Lee, Y.I.; Kang, B.S.; Kim, W.J.; et al. Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2. Exp. Mol. Med. 2008, 40, 345–353.
21. Grifman, M.; Trepel, M.; Speece, P.; Gilbert, L.B.; Arap, W.; Pasqualini, R.; Weitzman, M.D. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 2001, 3, 964–975.
22. Foka, P.; Pourchet, A.; Hernandez-Alcoceba, R.; Doumba, P.P.; Pissas, G.; Kouvatsis, V.; Dalagiorgou, G.; Kazazi, D.; Marconi, P.; Foschini, M.; et al. Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors. J. Gene Med. 2010, 12, 956–967.
23. Froelich, S.; Ziegler, L.; Stroup, K.; Wang, P. Targeted gene delivery to cd117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule. Biotechnol. Bioeng. 2009, 104, 206–215.
24. Jaggar, R.T.; Chan, H.Y.; Harris, A.L.; Bicknell, R. Endothelial cell-specific expression of tumor necrosis factor-alpha from the kdr or e-selectin promoters following retroviral delivery. Hum. Gene Ther. 1997, 8, 2239–2247.
25. Little, E.; Ramakrishnan, M.; Roy, B.; Gazit, G.; Lee, A.S. The glucose-regulated proteins (grp78 and grp94): Functions, gene regulation, and applications. Crit. Rev. Eukaryot. Gene Expr. 1994, 4, 1–18.
26. Allen, C.; Vongpunsawad, S.; Nakamura, T.; James, C.D.; Schroeder, M.; Cattaneo, R.; Giannini, C.; Krempski, J.; Peng, K.W.; Goble, J.M.; et al. Retargeted oncolytic measles strains entering via the egfrviii receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res. 2006, 66, 11840–11850.
27. Gotoh, A.; Ko, S.C.; Shirakawa, T.; Cheon, J.; Kao, C.; Miyamoto, T.; Gardner, T.A.; Ho, L.J.; Cleutjens, C.B.; Trapman, J.; et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J. Urol. 1998, 160, 220–229.
28. Broccoli, D.; Young, J.W.; de Lange, T. Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl. Acad. Sci. USA 1995, 92, 9082–9086.
29. Ishikawa, H.; Nakata, K.; Mawatari, F.; Ueki, T.; Tsuruta, S.; Ido, A.; Nakao, K.; Kato, Y.; Ishii, N.; Eguchi, K.; et al. Utilization of variant-type of human alpha-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma. Gene Ther. 1999, 6, 465–470.
30. Zhang, G.; Liu, T.; Chen, Y.H.; Chen, Y.; Xu, M.; Peng, J.; Yu, S.; Yuan, J.; Zhang, X. Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. Clin. Cancer Res. 2009, 15, 201–207.
31. Herz, K.; Heinemann, J.C.; Hesse, M.; Ottersbach, A.; Geisen, C.; Fuegemann, C.J.; Roll, W.; Fleischmann, B.K.; Wenzel, D. Live monitoring of small vessels during development and disease using the flt-1 promoter element. Basic Res. Cardiol. 2012, 107, 1–14.
32. Dong, D.; Dubeau, L.; Bading, J.; Nguyen, K.; Luna, M.; Yu, H.; Gazit-Bornstein, G.; Gordon, E.M.; Gomer, C.; Hall, F.L.; et al. Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors. Hum. Gene Ther. 2004, 15, 553–561.
33. Zhang, L.H.; Zhang, X. Roles of grp78 in physiology and cancer. J. Cell. Biochem. 2010, 110, 1299–1305.
34. Pfaffenbach, K.T.; Lee, A.S. The critical role of grp78 in physiologic and pathologic stress. Curr. Opin. Cell Biol. 2011, 23, 150–156.
35. Lee, A.S. Grp78 induction in cancer: Therapeutic and prognostic implications. Cancer Res. 2007, 67, 3496–3499.
36. Dong, D.; Stapleton, C.; Luo, B.; Xiong, S.; Ye, W.; Zhang, Y.; Jhaveri, N.; Zhu, G.; Ye, R.; Liu, Z.; et al. A critical role for grp78/bip in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res. 2011, 71, 2848–2857.
37. Wang, G.; Yang, Z.Q.; Zhang, K. Endoplasmic reticulum stress response in cancer: Molecular mechanism and therapeutic potential. Am. J. Transl. Res. 2010, 2, 65–74.
38. Pyrko, P.; Schonthal, A.H.; Hofman, F.M.; Chen, T.C.; Lee, A.S. The unfolded protein response regulator grp78/bip as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 2007, 67, 9809–9816.
39. Azatian, A.; Yu, H.; Dai, W.; Schneiders, F.I.; Botelho, N.K.; Lord, R.V. Effectiveness of hsv-tk suicide gene therapy driven by the grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas. J. Gastrointest. Surg. 2009, 13, 1044–1051.
40. Kia, A.; Przystal, J.M.; Nianiaris, N.; Mazarakis, N.D.; Mintz, P.J.; Hajitou, A. Dual systemic tumor targeting with ligand-directed phage and grp78 promoter induces tumor regression. Mol. Cancer Ther. 2012, 11, 2566–2577.
41. Pasqualini, R.; Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 1996, 380, 364–366.
42. Hajitou, A.; Pasqualini, R.; Arap, W. Vascular targeting: Recent advances and therapeutic perspectives. Trends Cardiovasc. Med. 2006, 16, 80–88.
43. Folkman, J. Addressing tumor blood vessels. Nat. Biotechnol. 1997, 15, 510, doi:10.1038/nbt0697-510.
44. Li, S.D.; Huang, L. Gene therapy progress and prospects: Non-viral gene therapy by systemic delivery. Gene Ther. 2006, 13, 1313–1319.
45. Waehler, R.; Russell, S.J.; Curiel, D.T. Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 2007, 8, 573–587.
46. Bouard, D.; Alazard-Dany, D.; Cosset, F.L. Viral vectors: From virology to transgene expression. Br. J. Pharmacol. 2009, 157, 153–165.
47. Kay, M.A. State-of-the-art gene-based therapies: The road ahead. Nat. Rev. Genet. 2011, 12, 316–328.
48. Green, N.K.; Seymour, L.W. Adenoviral vectors: Systemic delivery and tumor targeting. Cancer Gene Ther. 2002, 9, 1036–1042.
49. McCormick, F. Onyx-015 selectivity and the p14arf pathway. Oncogene 2000, 19, 6670–6672.
50. Oosterhoff, D.; Pinedo, H.M.; Witlox, M.A.; Carette, J.E.; Gerritsen, W.R.; van Beusechem, V.W. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus addelta24. Gene Ther. 2005, 12, 1011–1018.
51. Duan, D.; Sharma, P.; Yang, J.; Yue, Y.; Dudus, L.; Zhang, Y.; Fisher, K.J.; Engelhardt, J.F. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 1998, 72, 8568–8577.
52. Buning, H.; Perabo, L.; Coutelle, O.; Quadt-Humme, S.; Hallek, M. Recent developments in adeno-associated virus vector technology. J. Gene Med. 2008, 10, 717–733.
53. Lang, L.H. Fda approves use of bacteriophages to be added to meat and poultry products. Gastroenterology 2006, 131, 1370, doi:10.1053/j.gastro.2006.10.012.
54. Hajitou, A.; Trepel, M.; Lilley, C.E.; Soghomonyan, S.; Alauddin, M.M.; Marini, F.C., 3rd; Restel, B.H.; Ozawa, M.G.; Moya, C.A.; Rangel, R.; et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006, 125, 385–398.
55. Hajitou, A.; Rangel, R.; Trepel, M.; Soghomonyan, S.; Gelovani, J.G.; Alauddin, M.M.; Pasqualini, R.; Arap, W. Design and construction of targeted aavp vectors for mammalian cell transduction. Nat. Protoc. 2007, 2, 523–531.
56. Tandle, A.; Hanna, E.; Lorang, D.; Hajitou, A.; Moya, C.A.; Pasqualini, R.; Arap, W.; Adem, A.; Starker, E.; Hewitt, S.; et al. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer 2009, 115, 128–139.
57. Paoloni, M.C.; Tandle, A.; Mazcko, C.; Hanna, E.; Kachala, S.; Leblanc, A.; Newman, S.; Vail, D.; Henry, C.; Thamm, D.; et al. Launching a novel preclinical infrastructure: Comparative oncology trials consortium directed therapeutic targeting of tnfalpha to cancer vasculature. PLoS One 2009, 4, e4972.
58. Trepel, M.; Stoneham, C.A.; Eleftherohorinou, H.; Mazarakis, N.D.; Pasqualini, R.; Arap, W.; Hajitou, A. A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer. Mol. Cancer Ther. 2009, 8, 2383–2391.
59. Grassi, G.; Maccaroni, P.; Meyer, R.; Kaiser, H.; D’Ambrosio, E.; Pascale, E.; Grassi, M.; Kuhn, A.; di Nardo, P.; Kandolf, R.; et al. Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line u87. Carcinogenesis 2003, 24, 1625–1635.
60. Das, P.M.; Singal, R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22, 4632–4642.
61. Chen, W.Y.; Townes, T.M. Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation. Proc. Natl. Acad. Sci. USA 2000, 97, 377–382.
62. Kia, A.; Yata, T.; Hajji, N.; Hajitou, A. Inhibition of histone deacetylation and DNA methylation improves gene expression mediated by the adeno-associated virus/phage in cancer cells. Viruses 2013, 5, 2561–2572.
63. Hsu, C.C.; Li, H.P.; Hung, Y.H.; Leu, Y.W.; Wu, W.H.; Wang, F.S.; Lee, K.D.; Chang, P.J.; Wu, C.S.; Lu, Y.J.; et al. Targeted methylation of cmv and e1a viral promoters. Biochem. Biophys. Res. Commun. 2010, 402, 228–234.